Pharma News: VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA) & ACADIA Pharmaceuticals Inc. (ACAD)

Arena Pharmaceuticals, Inc (NASDAQ:ARNA) shares up by 7.12% (WallStreetPR)
The share prices of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has been advanced by 7.12 percent to close at $8.05 per share for the end of Friday on last trading session. The openings price of the share is $7.54 per share. The shares of the company had been trading in $7.48 to $8.17 per share range during the trading day. The shares of the company had thereby a 52 week high price level of $13.50 per share and the 52 week low price level of the company is at $6.95 per share. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is generally a biopharmaceutical company focused on discovering, commercializing and developing drugs that target Gprotein- coupled receptors (GPCRs). The company’s research and development programs also include the GPR119 with earlier stage programs that span several therapeutic areas.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)’s Pimavanserin is capable of realizing $1 billion in sales (WallStreetPR)
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) traded at $17.82 in the previous trading session after going upwards by $1.02 (or 6.07%). The stock hit its day’s low at $16.79 and day’s high at $17.96. Around 2.82 million shares have traded in the previous session while the average volume of the stock is 4.04 million shares. There was a surge in the activity of the investors which brought upon good news for many biotechnological companies.  ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is one of them. It has plenty to talk about, in 2013. Pimavanserin, a drug which has proven to be very effective in the treatment of Parkinson’s disease has brought a whole bunch of news for the investors for which they can get excited about.

ACADIA Pharmaceuticals Inc. : Wall Street Fundamentals Releases New In-Depth Stock Reports on ACAD, ACHN, CLDX and KERX (4-Traders)
The biotech industry?s surge in 2013 seems to have cooled in recent weeks as the sector has been hit by a broad slump in the markets. The SPDR S&P Biotech (ETF) (NYSEARCA:XBI) and the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) have posted declines of 3.65 and 4.04 percent in the past week. Federal Reserve Chairman Ben Bernanke?s comments hinting that bond purchases may be scaled back later this year sent markets sliding sharply this past week. Although it may not have a major effect on the Biotech sector in the long run it has made investors more susceptible to news triggering them to take gains or cut losses.